Anti-ADAM17 antibody [D1 (A12)] - BSA and Azide free,Abcam,AB215268

ADAM multidomain topology was exploited by first isolating an inhibitory human antibody (D1) that bound TACE-specific noncatalytic regions exclusively through its variable heavy (VH) domain. A D1-VH biased scFv phage-display library was then used to selectively isolate a new variable light (VL) chain that could simultaneously bind to the TACE catalytic domain. The resulting "cross-domain" human IgG1 antibody [D1(A12)] ab215268 is a previously undescribed biochemically holistic ADAM ectodomain inhibitor and demonstrates a unique alternative to small-molecule metalloprotease inhibition. Note from inventor: ab215268 is conformation sensitive and sees only a specific form of the native enzyme (reflecting its redox state). It does not work by IHC or WB. It was designed as a potential drug, active in native situations.

Host

Human

Reactivity

Human

Application

FuncS

Platform ID

BAB020711876

Abcam

Headquarters

Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX UK

Contact

Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215

Product Specifications
Scientific Background

Specifications

NameAnti-ADAM17 antibody [D1 (A12)] - BSA and Azide free
Cat. No.AB215268
HostHuman
IsotypeIgG1
ReactivityHuman
ApplicationFuncS
ClonalityMonoclonal
Clone NumberD1 (A12)
Concentration1 mg/mL Batch dependent concentration
ImmunogenRecombinant Fragment Protein within Human ADAM17. The exact immunogen used to generate this antibody is proprietary information.
Appearance/FormLiquid
ShippingBlue Ice
FormulationConstituents: PBS
Storage-20°C
Regulatory StatusResearch Use Only

Scientific Background

Target data Transmembrane metalloprotease which mediates the ectodomain shedding of a myriad of transmembrane proteins including adhesion proteins, growth factor precursors and cytokines important for inflammation and immunity (PubMed : 24226769, PubMed : 24227843, PubMed : 28060820, PubMed : 28923481). Cleaves the membrane-bound precursor of TNF-alpha to its mature soluble form (PubMed : 36078095, PubMed : 9034191). Responsible for the proteolytical release of soluble JAM3 from endothelial cells surface (PubMed : 20592283). Responsible for the proteolytic release of several other cell-surface proteins, including p75 TNF-receptor, interleukin 1 receptor type II, p55 TNF-receptor, transforming growth factor-alpha, L-selectin, growth hormone receptor, MUC1 and the amyloid precursor protein (PubMed : 12441351). Acts as an activator of Notch pathway by mediating cleavage of Notch, generating the membrane-associated intermediate fragment called Notch extracellular truncation (NEXT) (PubMed : 24226769). Plays a role in the proteolytic processing of ACE2 (PubMed : 24227843). Plays a role in hemostasis through shedding of GP1BA, the platelet glycoprotein Ib alpha chain (By similarity). Mediates the proteolytic cleavage of LAG3, leading to release the secreted form of LAG3 (By similarity). Mediates the proteolytic cleavage of IL6R, leading to the release of secreted form of IL6R (PubMed : 26876177, PubMed : 28060820). Mediates the proteolytic cleavage and shedding of FCGR3A upon NK cell stimulation, a mechanism that allows for increased NK cell motility and detachment from opsonized target cells. Cleaves TREM2, resulting in shedding of the TREM2 ectodomain (PubMed : 28923481). See full target information ADAM17

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.